Last reviewed · How we verify
ETC-1002
ETC-1002 activates AMP-activated protein kinase (AMPK) to reduce cholesterol synthesis and increase cholesterol catabolism, thereby lowering LDL cholesterol levels.
ETC-1002 activates AMP-activated protein kinase (AMPK) to reduce cholesterol synthesis and increase cholesterol catabolism, thereby lowering LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia (as monotherapy or in combination with statins), Cardiovascular risk reduction in patients with elevated LDL cholesterol.
At a glance
| Generic name | ETC-1002 |
|---|---|
| Also known as | bempedoic acid |
| Sponsor | Esperion Therapeutics, Inc. |
| Drug class | AMPK activator |
| Target | AMP-activated protein kinase (AMPK) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
ETC-1002 is an AMPK activator that works through dual mechanisms: it inhibits acetyl-CoA carboxylase (ACC), reducing fatty acid and cholesterol synthesis in the liver, and simultaneously increases cholesterol catabolism and excretion. This dual action results in significant reductions in LDL cholesterol and triglycerides, making it a novel approach to dyslipidemia management.
Approved indications
- Hypercholesterolemia and dyslipidemia (as monotherapy or in combination with statins)
- Cardiovascular risk reduction in patients with elevated LDL cholesterol
Common side effects
- Hyperuricemia
- Gout
- Elevated uric acid levels
- Tendon rupture
Key clinical trials
- A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia (PHASE3)
- A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1) (PHASE2)
- A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia (PHASE3)
- A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia (PHASE2)
- Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (PHASE3)
- Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension (PHASE2)
- A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance (PHASE2)
- A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ETC-1002 CI brief — competitive landscape report
- ETC-1002 updates RSS · CI watch RSS
- Esperion Therapeutics, Inc. portfolio CI